SILO PHARMA, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value
SILO PHARMA, INC. (SILO) had Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value of $6.77 per share as of 2025-12-04, per its 10-Q filed 2026-08-13.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue · last filed 2026-08-13
- 2025-12-04: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value $6.77; Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value as first filed $0.45.
- 2025-08-04: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value $11.64; Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value as first filed $0.78.
- 2025-05-22: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value $6.43; Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value as first filed $0.43.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value as first filed |
|---|---|---|
| 2025-12-04 | $6.77 10-Q · filed 2026-08-13 | $0.45 10-K · filed 2026-03-27 |
| 2025-08-04 | $11.64 10-Q · filed 2026-08-13 | $0.78 10-Q · filed 2025-11-13 |
| 2025-05-22 | $6.43 10-Q · filed 2026-08-13 | $0.43 10-Q · filed 2025-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |